Publications by authors named "Matthew Jarpe"

Claim this Profile
A
Author Correction: Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury.
Kerri D Pryce, Randal A Serafini, Aarthi Ramakrishnan, Andrew Nicolais, Ilinca M Giosan, Matthew Jarpe

Nat Neurosci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy.
David Michelson, William W Chin, Robert H Dworkin, Roy Freeman, David N Herrmann, Matthew Jarpe

Pain Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury.
Kerri D Pryce, Randal A Serafini, Aarthi Ramakrishnan, Andrew Nicolais, Ilinca M Giosan, Matthew Jarpe

Nat Neurosci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC-6 inhibition ameliorates the early neuropathology in a mouse model of Krabbe disease.
Sandra O Braz, Marlene M Morgado, Marta I Pereira, Ana C Monteiro, Olga Golonzhka, Matthew Jarpe

Front Mol Neurosci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valproate reverses mania-like behaviors in mice via preferential targeting of HDAC2.
Ryan W Logan, Angela R Ozburn, Rachel N Arey, Kyle D Ketchesin, Alicia Winquist, Matthew B Jarpe

Mol Psychiatry· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
Jingjing Ren, Michelle D Catalina, Kristin Eden, Xiaofeng Liao, Kaitlin A Read, Matthew Jarpe

Front Immunol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Farhana Sakloth, Lefteris Manouras, Kleopatra Avrampou, Vasiliki Mitsi, Randal A Serafini, Matthew Jarpe

Psychopharmacology (Berl)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model.
Elisabeth Rossaert, Eveliina Pollari, Tom Jaspers, Lawrence Van Helleputte, Matthew Jarpe

Acta Neuropathol Commun· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment.
Jiacheng Ma, XiaoJiao Huo, Matthew B Jarpe, Annemieke Kavelaars, Cobi J Heijnen

Acta Neuropathol Commun· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.
Jennifer S Gewandter, Joanna Brell, Guido Cavaletti, Patrick M Dougherty, Scott Evans, Matthew Jarpe

Neurology· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Lawrence Van Helleputte, Mandy Kater, Dana P Cook, Caroline Eykens, Elisabeth Rossaert, Matthew Jarpe

Neurobiol Dis· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients.
Wenting Guo, Maximilian Naujock, Laura Fumagalli, Tijs Vandoorne, Pieter Baatsen, Matthew Jarpe

Nat Commun· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Chengyin Min, Nathan Moore, Jeffrey R Shearstone, Steven N Quayle, Pengyu Huang, Matthew B Jarpe

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Karen Krukowski, Jiacheng Ma, Olga Golonzhka, Geoffroy O Laumet, Tanuja Gutti, Matthew B Jarpe

Pain· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
Veronick Benoy, Pieter Vanden Berghe, Matthew Jarpe, Philip Van Damme, Wim Robberecht

Neurotherapeutics· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Pengyu Huang, Ingrid Almeciga-Pinto, Matthew Jarpe, John H van Duzer, Ralph Mazitschek

Oncotarget· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2.
Jeffrey R Shearstone, Olga Golonzhka, Apurva Chonkar, David Tamang, John H van Duzer, Matthew B Jarpe

PLoS One· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice.
Nicole L Regna, Miranda D Vieson, Xin M Luo, Cristen B Chafin, Abdul Gafoor Puthiyaveetil, Matthew B Jarpe

Clin Immunol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice.
Tabassum Majid, Deric Griffin, Zachary Criss, Matthew Jarpe, Robia G Pautler

Alzheimers Dement (N Y)· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of canonical structure determining residues on antibody affinity and stability.
Louis A Clark, Stephen J Demarest, John Eldredge, Matthew B Jarpe, You Li

J Struct Biol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.
Karl J M Hanf, Joseph W Arndt, Ling Ling Chen, Matthew Jarpe, P Ann Boriack-Sjodin

Methods· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.
Jeanine Jochems, Janette Boulden, Bridgin G Lee, Julie A Blendy, Matthew Jarpe

Neuropsychopharmacology· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance.
Casey Cook, Yari Carlomagno, Tania F Gendron, Judy Dunmore, Kristyn Scheffel, Matthew Jarpe

Hum Mol Genet· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Loredana Santo, Teru Hideshima, Andrew L Kung, Jen-Chieh Tseng, David Tamang, Matthew Jarpe

Blood· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4.
Renée I Shapiro, Tatiana Plavina, Brian R Schlain, R Blake Pepinsky, Ellen A Garber, Matthew Jarpe

J Pharm Biomed Anal· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis